drugset / Trial / NCT04362449
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
This is an open label study for any patients with a bile duct cancer or gallbladder cancer, who will be treated with gemcitabine and cisplatin chemotherapy (the ABC02 regime). Patients recruited onto this study will have a reduction of their hydration time and be given Akynzeo as an anti-sickness drug, to assess tolerability compared to the current standard of care. The aim of this research is to assess the tolerability of a shorter hydration time, which may improve patient satisfaction as they would then spend less time in hospital having chemotherapy, saving both time and money for the institutions also.
Timeline
- Start
- 2019-01-02
- Primary completion
- 2023-02-02
- Completion
- 2023-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Akynzeo | Unknown | — | Oral |
| Subject | Ondansetron | Other / unclassified | — | Intravenous |